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Abstract
Purpose: A number of institutions have clinically implemented CYP2D6 genotyping to guide 
drug prescribing. We compared implementation strategies of early adopters of CYP2D6 testing, 
barriers faced by both early adopters and institutions in the process of implementing CYP2D6 
testing, and approaches taken to overcome these barriers.
Methods: We surveyed eight early adopters of CYP2D6 genotyping and eight institutions in the 
process of adoption. Data were collected on testing approaches, return of results procedures, 
applications of genotype results, challenges faced, and lessons learned.
Results: Among early adopters, CYP2D6 testing was most commonly ordered to assist with 
opioid and antidepressant prescribing. Key differences among programs included test ordering and 
genotyping approaches, result reporting, and clinical decision support. However, all sites tested for 
copy number variation and 9 common variants, and reported results in the medical record. Most 
sites provided automatic consultation and had designated personnel to assist with genotype-
informed therapy recommendations. Primary challenges were related to stakeholder support, 
CYP2D6 gene complexity, phenotype assignment, and sustainability.
Conclusion: There are specific challenges unique to CYP2D6 testing given the complexity of 
the gene and its relevance to multiple medications. Consensus lessons learned may guide those 
interested in pursuing similar clinical pharmacogenetic programs.
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The cytochrome P450 2D6 (CYP2D6) enzyme metabolizes approximately 25% of 
prescription drugs and nearly 40% of drugs frequently cited in adverse drug reaction 
studies1. The CYP2D6 enzyme is the primary metabolic enzyme for select opioids, 
antidepressants, anti-emetics, and tamoxifen. The CYP2D6 gene is highly polymorphic, 
which can have important consequences for drug safety and effectiveness.
The CYP2D6 gene has over 100 allelic variants and subvariants, which introduces a high 
degree of complexity for gene assays and interpretation2–4. Approximately 5 to 10 percent 
of individuals inherit two nonfunctional CYP2D6 alleles (e.g. *3, *4, *5) and are poor 
metabolizers (PMs) with no enzyme activity3. Two to 11 percent are intermediate 
metabolizers (IMs) with a combination of nonfunctional and decreased function (e.g. *41, 
*17) alleles and significant reductions in enzyme activity. An additional 1 to 2 percent are 
ultra-rapid metabolizers (UMs) with multiple CYP2D6 gene copies (e.g. *1/*1×2) and 
increased enzyme activity.
The consequences of CYP2D6 variation on drug response vary depending on whether the 
enzyme biotransforms the parent drug into a more active or less active metabolite. The 
prodrugs codeine, tramadol, and tamoxifen are biotransformed via CYP2D6 into metabolites 
with greater pharmacologic activity than their parent compounds. Compared to normal 
metabolizers (NMs), PMs and IMs have lower concentrations of the more potent metabolites 
and may fail to receive therapeutic benefit from these medications5–10. On the other hand, 
UMs produce higher concentrations of the more potent metabolites of codeine and tramadol 
compared to NMs 11,12, which increases risk for serious adverse events including respiratory 
depression and death secondary to toxic concentrations of more potent metabolites13,14.
The implications of CYP2D6 polymorphisms are different when CYP2D6 biotransforms 
drugs to less active metabolites, as with some selective serotonin reuptake inhibitors 
(SSRIs), tricyclic antidepressants, ondansetron, and tropisetron. Poor metabolizers treated 
with paroxetine, fluvoxamine, and tricyclic antidepressants are at increased risk for adverse 
drug effects secondary to higher plasma concentrations of the active parent drugs, whereas 
UMs are at risk for subtherapeutic concentrations of the parent drug and therapeutic 
failure15,16. While there is insufficient evidence on the consequences of reduced metabolism 
for ondansetron and tropisetron, reduced anti-emetic effects have been observed in 
UMs17–19.
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are available for 
each of the drugs discussed above3,15–17,20. Many institutions within the NIH-funded 
Implementing GeNomics In pracTicE (IGNITE) Network have clinically implemented, or 
are in the process of implementing, CYP2D6 genotyping to assist with drug prescribing21. 
We previously described experiences and challenges with clinical implementation of 
CYP2C19 genotype-guided antiplatelet therapy22. Given CYP2D6 gene complexity and 
relevance for multiple medications, it may present unique implementation challenges. The 
purpose of this paper is to compare goals and strategies for operationalizing CYP2D6 
genotype-guided therapy among early test adopters and summarize challenges faced by both 
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early adopters and those in the process of adoption and approaches to overcome key 
implementation barriers.
METHODS
Institutions within the IGNITE Network Pharmacogenetics Working Group, a collaboration 
of pharmacogenetic researchers and implementers who share data and real‐world 
experiences to advance genomic medicine, were invited to participate. All participating 
institutions had implemented CYP2D6 testing into practice or were in the process of 
implementation.
An existing data collection tool was adapted to capture experiences of sites implementing 
CYP2D6 genotyping22. Data elements included the testing landscape, stakeholder 
involvement, testing application, genotyping approaches, return of results procedures, 
clinical decision support (CDS), education strategies, challenges faced and lessons learned. 
A second tool was designed to collect data on the testing landscape, planned test 
applications, and initial challenges from sites in the process of establishing CYP2D6 testing. 
Data elements were selected and refined through discussions at in-person group meetings 
and teleconferences from September 2017 to December 2017 for the initial tool and January 
2018 to May 2018 for the second tool. Challenges faced across sites and recommendations 
for overcoming challenges were aggregated to a consensus list through teleconference 
discussions. This research was approved as exempt by the University of Florida Institutional 
Review Board.
RESULTS
Early adopters of CYP2D6 testing
Institutional landscape and CYP2D6 test implementation planning—As of July 
2018, 8 institutions in the IGNITE Network had implemented CYP2D6 genotyping and 
contributed information on implementation strategies (Table 1). Two institutions (Cincinnati 
Children’s Hospital Medical Center [CCHMC] and Indiana University School of Medicine 
[IU]) launched CYP2D6 testing in conjunction with testing for multiple other genes. All 
others had previously implemented testing for other genes – most commonly for CYP2C19 
to guide antiplatelet therapy after coronary intervention and TPMT to guide thiopurine 
dosing. Four of the programs were solely clinical implementations, while 4 included 
research components. At 7 institutions, a formal precision medicine team, usually including 
a pharmacist, health informatics expert(s), and physician stakeholders, led the design and 
initiation of CYP2D6 testing and provided program oversight (Figure 1A, Table S1). An 
individual physician champion specializing in psychiatry led the initiative at the University 
of Alabama at Birmingham (UAB).
Clinical applications of CYP2D6 testing and genotyped populations—Most 
institutions reported multiple indications for which CYP2D6 genotyping was ordered 
(Figure 1B, Table S1), with antidepressant and opioid prescribing being the most common. 
Other indications included prescribing of antiemetic and antipsychotic agents. Three sites 
reported limited instances of CYP2D6 testing to assist with tamoxifen prescribing.
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Most institutions used both reactive (e.g., test ordered at time of drug prescribing) and pre-
emptive (e.g., test ordered to assist with future prescribing) genotyping models (Table S1). 
At IU, the CYP2D6 test is part of a multi-gene panel ordered for patients prescribed any 
drug with CPIC Level A evidence23. In this regard, if the prescription triggering the 
genotype order was for a CYP2D6 substrate drug (e.g. opiate, SSRI), CYP2D6 genotyping 
would be reactive. Otherwise, CYP2D6 testing would be done pre-emptively as part of the 
panel to inform future prescribing of CYP2D6 substrates. Similar models were in place at 
Vanderbilt University Medical Center (VUMC) and Sanford Health. Other pre-emptive 
models included testing of patients with depressive symptoms to assist with initial 
prescribing of antidepressants or antipsychotics, testing patients pre-operatively to assist 
with opioid prescribing, and testing for primary care patients as part of a pilot 
pharmacogenetic implementation project. One site had a reactive only testing model where 
genotyping was primarily reserved for patients with depression not responding to current 
therapy.
Genetic testing—The process for CYP2D6 test ordering varied among programs (Table 
S2). Prescribers electively placed genotype orders at 7 of 8 sites. Three of these sites also 
ordered clinical genotyping for participants in pharmacogenetic studies. At one site, 
CYP2D6 genotyping was preselected on the order set for patients admitted to a psychiatric 
unit as part of routine care.
Six sites performed testing onsite in a College of American Pathologists (CAP)/Clinical 
Laboratory Improvement Act (CLIA)-certified laboratory (Table S2). Deciding factors in 
choosing in-house testing (versus outsourcing) included having existing expertise and 
infrastructure for clinical genotyping, desire to have the ability to alter variants tested as 
evidence evolves, and in the case of very early adopters, the limited availability of 
commercial testing when the program began. While genotyping platforms varied across 
these sites, all tested and reported allele-defining variants for *2, *3, *4, *6, *9, *10, *17, 
and *41, at minimum, in addition to gene deletion (*5) and copy number variation (Figure 
2). Four institutions genotyped CYP2D6 as part of a multi-gene panel. Factors considered in 
genotyping platform selection were workflow; turn-around time; ability to batch samples, 
detect full gene deletion and duplication, and customize variants tested; capability for 
multiplexed targeted genotyping; and FDA clearance. Four sites had validated assays for 
blood and either buccal cell or saliva samples. Genotype test turnaround time ranged from 2 
to 14 business days across sites.
Two sites relied solely on commercial or reference laboratories for genotyping. Two sites 
with in-house genotyping capabilities also reported use of commercial laboratories in select 
cases, such as when patients preferred noninvasive sample collection and in-house 
genotyping was validated for blood samples only or when patient payment assistance, 
available through some commercial laboratories, was desired. Factors influencing the choice 
of outside laboratory included which genes were tested besides CYP2D6, cost of testing, 
characteristics of patient assistance programs, and provider knowledge/awareness of a 
specific laboratory.
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Phenotype assignment—All but one site reported CYP2D6 phenotype assignment 
based on activity scores as described in the current CPIC guidelines3; IU classified patients 
with one no-function and one normal function allele (e.g. *1/*4) as NM for codeine, per 
CPIC guidelines, and as IM for tramadol, per Dutch Pharmacogenetic Working Group 
guidelines24. Three sites reported that either the laboratory report or patient-specific clinical 
consult note mentioned of use of CYP2D6 inhibitors that can cause phenoconversion (i.e. 
change the phenotype from that predicted based on genotype alone).
Communication of results, approach to therapy modification, and education 
strategies—All institutions reported CYP2D6 test results in the EHR, usually within the 
“laboratory results” section (Table S3). Six sites reported both CYP2D6 genotype and 
predicted phenotype (metabolizer status) in the laboratory report, and two sites (CCHMC 
and IU) additionally provided genotype-specific drug therapy recommendations. All but one 
institution had a designated service or pharmacist available to provide genotype-informed 
drug therapy recommendations, and 4 institutions provided an automatic consultation via 
personal communication or an electronic consult note. Five of 8 sites provided downstream 
alerting or electronic CDS triggered with future drug orders within the EHR, most 
commonly with codeine, tramadol, and antidepressants. A sixth site was in the process of 
building electronic CDS.
Five programs provided patients with their test results via a patient web portal. Most 
programs provided education to patients about CYP2D6 testing through disseminated 
brochures, pamphlets, or other literature, or in-person education. Authors reported that 
providers were most engaged when education was delivered through focused discussions 
with providers who prescribe the target drugs, particularly when directly related to a patient 
case, and in-services to specialty groups.
Institutions in the process of implementing CYP2D6 testing into practice
Eight institutions were in the process of CYP2D6 implementation (Table S4). All but one 
had previously implemented testing of other genes, with CYP2C19 being most common. 
Precision medicine “teams” or “steering committees” were the drivers of these efforts at 
most sites. Four institutions were in the process of engaging stakeholders and leadership 
support. Development of informatics-related support and resources and selection or 
validation of the genotyping platform were also commonly identified as a current step in the 
implementation process. Nearly all locations were weighing considerations related to panel 
(multi-gene) versus single gene testing and whether to conduct CYP2D6 testing internally 
versus through a reference laboratory. All but two institutions were planning to implement 
CYP2D6 testing as part of clinical practice (as opposed to a research protocol). Varying 
therapeutic areas were identified for implementation, although pain management and 
psychiatry were specifically noted by 6 and 5 institutions, respectively. Institutions 
anticipated deploying CYP2D6 testing in settings ranging from targeted populations and 
specific clinical care locations to a larger, institution-wide general patient population.
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Implementation challenges and lessons learned
Table 2 summarizes challenges reported and lessons learned across sites. A major challenge 
was the inability to determine which allele was duplicated or multiplicated for heterozygous 
genotypes with copy number variation (CNV), which often led to the inability to 
unambiguously assign phenotype. Further challenges were variable phenotype assignment 
based on the CYP2D6 substrate, and the potential for phenoconversion with concomitant 
CYP2D6 inhibitor use. An additional challenge reported by sites in the process of adopting 
testing was related to potential risk management issues in the event that appropriate action 
was not taken in response to genotype results. Sites reported that providers were especially 
concerned given the multiple drug substrates for CYP2D6 whose response may be impacted 
by genotype. This concern was not shared by sites that had already adopted testing, though 
they reported it was discussed prior to implementation.
Choosing genotyping methodology that detects copy number variation was felt to be critical 
in order to identify UMs (due to gene duplication) and some IMs (due to gene deletion). 
Recognizing that most genotype platforms at present cannot detect which allele is 
duplicated/multiplicated, sites agreed that a process must be in place for assigning 
phenotype for heterozygous genotypes with CNV to allow for appropriate reporting and 
downstream CDS25,26. Most sites used a ranged phenotype (e.g. NM to UM) when this 
occurred. Also ranked as important was having multidisciplinary stakeholder involvement 
and in particular, a physician champion, to facilitate implementation and additional 
stakeholder buy-in. It is in the authors’ consensus opinion, that while not required for 
implementation, in an ideal future state where feasible to do so, the following would also be 
in place to support the provision of CYP2D6 genotype-guided therapies: 1) noninvasive 
methods for DNA sample collection, especially for pediatric patients; 2) assay methods 
capable of assessing which allele was duplicated or multiplicated; 3) rapid or pre-emptive 
testing to minimize or eliminate delays in prescribing decisions; 4) CYP2D6 result 
(genotype and phenotype) reporting in an easily accessible location in the EHR, preferably 
one for lifetime results, and as discrete data to enable automated CDS; 5) automated CDS 
that accounts for phenoconversion secondary to use of CYP2D6 inhibitors; and 6) a 
mechanism for patients and providers to access genotype results throughout the patient’s 
life.
DISCUSSION
In surveying early adopters of CYP2D6 genotyping to guide prescribing decisions, we found 
multiple approaches to implementation, even within the same institution, with sites reporting 
use of both reactive and preemptive genotyping models, single and multi-gene testing, and 
clinical- and research-based deployment, much like in our previous report of implementation 
of CYP2C19-guided antiplatelet therapy22. Other similarities between implementing 
CYP2D6-guided therapies and CYP2C19-guided antiplatelet therapy22 included the role of a 
physician champion working alongside clinicians who ordered and applied test results 
clinically and use of a multi-disciplinary team approach, including pharmacists and health 
informatics experts, to lead implementation. While CYP2D6 testing was most commonly 
ordered to assist with antidepressant and opioid prescribing, most institutions applied 
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genotype results to multiple therapies. In addition, most sites had electronic CDS tools in 
place or under development and designated personnel to assist with interpretation and 
translation of genotype results to inform prescribing decisions. Provider education and 
building evidence to support the utility and cost effectiveness of testing were recognized as 
keys to driving greater stakeholder engagement.
There were also notable differences between CYP2D6 testing and CYP2C19-guided 
antiplatelet therapy22. Whereas CYP2C19-guided antiplatelet therapy was most often the 
first pharmacogenetic implementation, CYP2D6 genotyping was typically a subsequent 
deployment or only implemented as part of a larger, more comprehensive pharmacogenetics 
program. This may be reflective of the relative complexity of the CYP2D6 genotype and 
resultant challenges related to genotype procedures and phenotype assignment. In contrast to 
CYP2C19 where all institutions deployed testing on site, half of the early adopters of 
CYP2D6 testing leveraged external reference labs as primary or supporting CYP2D6 testing 
facilities. For CYP2C19-guided antiplatelet therapy, institutional efforts were focused on a 
single use case and engaged the interventional cardiology practitioners. This allowed for 
highly tailored workflows and targeted educational efforts. In our experiences, CYP2D6 
implementation efforts, in contrast, required engaging practitioners across multiple practice 
areas (e.g. psychiatry, primary care, surgery, and oncology) given the multiple drug 
substrates for the CYP2D6 enzyme (e.g. antidepressants, opioids, anti-emetics, tamoxifen). 
This may require a broader strategy and more extensive educational effort to rally the 
practice groups in acceptance and adoption of CYP2D6 genotype-guided medication 
therapy. In addition, unlike CYP2C19 testing for antiplatelet guidance where patients are 
undergoing an invasive procedure and collection of a blood sample for genotyping was not 
an issue, having a non-invasive sample collection method for CYP2D6 testing was deemed 
important as it is commonly done in an outpatient setting where phlebotomy may not be 
available or for children who may be especially averse to blood collection.
There were several common challenges with CYP2D6-guided therapy. Some were technical 
in nature and related to CYP2D6 gene complexity, with variation including single nucleotide 
polymorphisms, deletions and multiple copies of the entire gene, and fusions with 
downstream pseudogenes4. As the field moves more towards whole genome sequencing, 
these unique characteristics of CYP2D6 make extracting the accurate information from short 
read whole genome sequencing difficult and requiring special informatics approaches to 
accurately call the alleles27,28. Thus, sites agreed that local CYP2D6 expertise was an 
important asset to implementation, and in the absence of such, sites may prefer to utilize a 
commercial laboratory for genotyping.
Despite gene complexity and independent assay development, there is remarkable similarity 
across sites in the variants tested. No site was performing comprehensive analysis of all 
known CYP2D6 variants, and each site tested for copy number variation and assays enabling 
the assignment of 9 common alleles. While having a list of “must-test alleles” would be 
helpful to guide assay development, in the absence of that, the list of variants tested across 
sites may be useful for other institutions considering CYP2D6 testing.
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A second layer of technical challenges surround reporting test results in EHRs and use of 
results in CDS. Many systems do not have mature EHR systems in place for storing, 
reporting, and using genetic results. Historically, many genetic testing results have been 
reported in EHRs in text-based reports or scanned documents. Building the technical 
capability for genetic results to be stored as discrete data enables downstream applications 
like genotype specific electronic CDS but requires an initial investment and ongoing 
maintenance. In addition, accounting for use of CYP2D6 inhibitors is important for refining 
CYP2D6 phenotype given evidence of altered enzyme activity, disposition of CYP2D6 
substrates, and drug response with CYP2D6 inhibitors29–32. Strong inhibitors (e.g. 
paroxetine) can convert NMs, based on genotype results, to PMs, whereas moderate 
inhibitors (e.g. duloxetine) can convert NMs, based on genotype, to IMs3,32. More 
sophisticated decision support may be necessary to account for this phenoconversion with 
concomitant use of CYP2D6 inhibitors.
Challenges that were specific to the early implementation phase included the unknown 
ramifications of failure to act on genotype results, especially since CYP2D6 genotype has 
implications for multiple therapies, and having sufficient personnel in place to facilitate 
implementation. Interestingly, early test adopters stated that potential risk management 
issues were discussed prior to implementation but are no longer perceived as a barrier, 
indicating that potential risk ramifications around pharmacogenetic testing are a common 
perceived obstacle, but may not be a practical reality at this time. Indeed, there are limited 
examples of a legal action involving the use or lack of use of pharmacogenetic information 
in clinical practice33. Regarding personnel, early adopters were able to overcome this 
obstacle by engaging across departments, teams, and services to build multidisciplinary 
teams. Of note, the effort of those teams is ongoing, as CYP2D6 testing and 
pharmacogenetic CDS requires maintenance in the face of laboratory and EHR changes, and 
continual assessment of new developments in all aspects from variant detection to 
prescribing advice.
Strengths of this research are the inclusion of multiple institutions and different applications 
of genotype results, increasing the generalizability of challenges faced and lessons learned. 
A potential limitation is that all institutions were from a common research network and 
approaches to implementation may be similar for this reason. In addition, we do not provide 
data on specific recommendations provided or implementation success metrics as our intent 
was to survey the landscape of CYP2D6 testing across multiple sites. Future studies may 
focus on individual applications of CYP2D6 testing. While we provide information on the 
platforms used for genetic testing, it was beyond the scope of the paper to provide details on 
genotyping methodology in each laboratory. Finally, we do not address the cost of 
implementation or genetic testing. The cost of analytical validation can be significant with a 
new laboratory test (approximately $30,000 in reagents alone based on personal 
observations [V.M.P.]), and increase further if the laboratory has to invest in new equipment. 
The cost of genetic testing for institutions and patients or payors is influenced by multiple 
factors, including technology used for the assay, turn-around time, number of samples, and 
state-specific rules and regulations. With evolving technology and policies, genotyping costs 
are also variable over time.
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In summary, despite of the complexity of the CYP2D6 genotype and associated challenges 
with genotype interpretation and phenotype assignment, multiple institutions have 
prioritized implementation of CYP2D6 genotyping to inform drug prescribing. To our 
knowledge, this is the first description of strategies for CYP2D6 testing to guide drug 
prescribing across multiple sites along with challenges faced and important lessons learned. 
Implementation resources from our sites, including supporting literature, CDS language, and 
education materials are available through the IGNITE website (https://ignite-genomics.org/). 
Our experiences and lessons learned may be valuable for other institutions seeking to 
implement CYP2D6 testing.
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Groups enabling CYP2D6 genotype implementation at 8 early adopters of testing.
EHR, electronic health records; CTSI, Clinical Translational Science Institute
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Target drugs for CYP2D6 genotyping among 8 early adopters.
SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant
*aripiprazole, haloperidol, olanzapine, perphenazine, risperidone, thioridazine, venlafaxine, 
atomoxetine
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CYP2D6 variations tested across sites
Dup, duplications
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Table 2.
Primary implementation challenges and lessons learned
Challenges Lessons learned
Obtaining provider/stakeholder buy-in
• Limited provider exposure to pharmacogenetics and 
awareness about genotyping availability.
• Limited data on clinical utility of CYP2D6 genotype-
guided drug therapy.
• Having broad, multidisciplinary program buy-in, including a physician champion, 
facilitates implementation.
• Important to educate providers about testing availability and applications to 
prescribing decisions and to engage physicians when building CDS language.
Sample collection and CYP2D6 genotyping
• Multiple single nucleotide variants, gene deletion, 
duplication, and multiplication define alleles
• Difficult to quantitate duplication/multiplication or 
determine which allele is duplicated/multiplicated in 
heterozygotes
• Noninvasive sample collection method facilitates testing for children and when no 
phlebotomy services are available on site.
• Saliva and buccal cell samples can give inconsistent copy number results
• CYP2D6 genotype expertise important for establishing genotyping procedures 
and interpreting results.
• Platform must be able to detect gene deletion and copy number variation, with a 
process should be in place for indeterminate genotypes due to copy number 
variation
Genotype reporting and phenotype assignment
• Large number of possible CYP2D6 diplotypes 
complicates automation of EHR processes.
• Phenotype assignment may vary depending on drug 
substrate.a
• Moderate to strong CYP2D6 inhibitors can cause 
phenoconversion
• EHR changes may interfere with functioning of 
electronic CDS.
• Genotypes should be reported in a consistent location in the EHR.
• Entering genotype results as discrete data enables genotype specific electronic 
CDS.
• Designated personnel and/or electronic CDS are important to assist with 
integrating genotype results into prescribing decisions.
• Need CDS system that assigns phenotype based on drug substrate and accounts 
for phenoconversion
• Quality control procedures are important for ensuring electronic CDS maintained 
with EHR updates
Sustainability
• Building a reimbursement model
• Updates to genotype reports and automated CDS 
needed as evidence evolves to support genotype-guided 
prescribing for additional medications.
• Clinical outcomes and cost-effectiveness data may support reimbursement and 
additional stakeholder buy-in.
• Personnel need to stay abreast of scientific developments in the field and update 
reports and decision support as needed.
Personnel issuesb
• Having sufficient personnel to direct and support 
implementation
• Create partnerships with pharmacists or other clinicians on clinical teams through 
a decentralized model
Risk management issuesb
• Concern if there is an actionable variant and no one acts 
on it
• While risk management issues may be part of the discussion prior to 
implementation, they were no longer voiced as a concern post-implementation
aCombination of one normal function allele plus one no function allele may be assigned the intermediate metabolizer phenotype for tamoxifen, but 
the normal metabolizer phenotype for codeine, tricyclic antidepressants, and select selective serotonin reuptake inhibitors).14,15,19
bChallenges specific to institutions in the process of implementing
CDS, clinical decision support; EHR, electronic health record
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